X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (43) 43
female (33) 33
index medicus (28) 28
male (26) 26
middle aged (25) 25
adult (24) 24
environmental sciences (20) 20
public, environmental & occupational health (20) 20
immunotherapy (19) 19
melanoma (19) 19
oncology (18) 18
aged (13) 13
animals (12) 12
cancer (11) 11
poland (10) 10
work-related symptoms (10) 10
dust (9) 9
ipilimumab (9) 9
metastatic melanoma (8) 8
occupational exposure (8) 8
organic dust (8) 8
pantoea agglomerans (8) 8
adolescent (7) 7
agricultural workers' diseases - etiology (7) 7
agriculture (7) 7
cancer vaccines (7) 7
mice (7) 7
occupational exposure - adverse effects (7) 7
skin tests (7) 7
agricultural workers' diseases - immunology (6) 6
airborne microorganisms (6) 6
allergy (6) 6
antigens, bacterial - immunology (6) 6
chemistry (6) 6
endotoxin (6) 6
melanoma - drug therapy (6) 6
metallurgy (6) 6
spirometry (6) 6
air microbiology (5) 5
allergens (5) 5
bacteria (5) 5
care and treatment (5) 5
cell biology (5) 5
dust - analysis (5) 5
erwinia-herbicola (5) 5
farmers (5) 5
fungi (5) 5
herbs (5) 5
hypersensitivity pneumonitis (5) 5
immunology (5) 5
lncrna (5) 5
mice, inbred c57bl (5) 5
organic dusts (5) 5
research (5) 5
abridged index medicus (4) 4
acyclic or carbocyclic compounds (4) 4
allergens - immunology (4) 4
analysis (4) 4
biomarker (4) 4
breast cancer (4) 4
cotton dust (4) 4
creep (4) 4
dacarbazine (4) 4
damage (4) 4
dendritic cells (4) 4
efficacy (4) 4
endotoxins (4) 4
life sciences (4) 4
measuring (4) 4
medicine (4) 4
melanoma - pathology (4) 4
organic chemistry (4) 4
original paper (4) 4
pantoea - physiology (4) 4
phase-ii (4) 4
physics (4) 4
poland - epidemiology (4) 4
prevalence (4) 4
prostate cancer (4) 4
respiratory function tests (4) 4
skin neoplasms - drug therapy (4) 4
survival (4) 4
testing (4) 4
therapy (4) 4
treatment outcome (4) 4
5700 (3) 3
advanced melanoma (3) 3
agricultural workers' diseases - epidemiology (3) 3
air pollutants, occupational - adverse effects (3) 3
allergic alveolitis (3) 3
animal experiments (3) 3
antigens, fungal - immunology (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
asthma (3) 3
borne bacteria (3) 3
braf (3) 3
braf inhibitor (3) 3
cancer vaccine (3) 3
cancer vaccines - administration & dosage (3) 3
cancer vaccines - immunology (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1997, Zeszyty katyńskie, ISBN 838648232X, Volume nr 7, 2 v. in 1 (496 p.)
Book
Medicine (United States), ISSN 0025-7974, 12/2014, Volume 93, Issue 27
Journal Article
细胞研究:英文版, ISSN 1001-0602, 2015, Volume 25, Issue 2, pp. 208 - 224
Journal Article
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, ISSN 1871-5206, 2019, Volume 19, Issue 5, pp. 580 - 586
Journal Article
Wspolczesna Onkologia, ISSN 1428-2526, 2017, Volume 2, Issue 1A, pp. 68 - 72
The treatment landscape in advanced melanoma is changing dramatically with the approval of new drugs. Vemurafenib was the first approved targeted agent for the... 
BRAF inhibitors | MEK inhibitors | Melanoma | melanoma | Review
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 616 - 622
Journal Article
Wspolczesna Onkologia, ISSN 1428-2526, 2017, Volume 21, Issue 1, pp. 1 - 5
The treatment landscape of advanced melanoma has changed significantly following the discovery and marketing authorisation of immune checkpoints inhibitors.... 
Immunotherapy | Melanoma | Anti-PD1 | Medical prognosis | Apoptosis | melanoma | anti-PD1 | Review Paper | immunotherapy
Journal Article
Medicine, ISSN 0025-7974, 12/2014, Volume 93, Issue 27, p. e157
About 40% to 60% of melanomas present BRAF mutation. Selective BRAF inhibitors such as vemurafenib and dabrafenib are currently approved for the treatment of... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | BRAF | RETREATMENT | INHIBITOR | PROGRESSION | Neoplasm Metastasis | Skin Neoplasms - drug therapy | Humans | Melanoma - drug therapy | Middle Aged | Drug Resistance, Neoplasm | Female | Antineoplastic Agents - administration & dosage | Indoles - administration & dosage | Sulfonamides - administration & dosage
Journal Article
Cell Research, ISSN 1001-0602, 02/2015, Volume 25, Issue 2, pp. 208 - 224
The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces immune-mediated long-term control of metastatic melanoma in a fraction of... 
sCD25 | tumor immunotherapy | ipilimumab | IL-2 | cancer | CTLA-4 blockade | Original | CD122
Journal Article
Wspolczesna Onkologia, ISSN 1428-2526, 2012, Volume 16, Issue 5, pp. 363 - 370
The incidence of melanoma is increasing steadily both in Poland and worldwide. Until 2010 three drugs were approved for the treatment of metastatic melanoma -... 
Cancer vaccines | BRAF inhibitor | Anti-CTLA4 | Immunotherapy | Melanoma | SURVIVAL | DENDRITIC CELLS | cancer vaccines | melanoma | BRAF | DACARBAZINE | COMBINATION | anti-CTLA4 | METASTATIC MELANOMA | THERAPY | ONCOLOGY | immunotherapy | MUTATIONS | CLINICAL-RESPONSE | IPILIMUMAB | Review
Journal Article
Journal of Pressure Vessel Technology, Transactions of the ASME, ISSN 0094-9930, 2014, Volume 136, Issue 4, p. 41408
Thick-walled, main stream pipelines are key elements in many power and chemical plants. Operating for a long time in high temperature and subjected to internal... 
ENGINEERING, MECHANICAL | CREEP | Measurement | Usage | Ultrasonic waves | Mechanical properties | Pipe | Distances | Methods
Journal Article
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, ISSN 1871-5206, 2019, Volume 19, Issue 3, pp. 290 - 303
Background: Head and neck squamous cell carcinoma (HNSCC) is the most common malignant cancer occurring in the head and neck area, approximately 90% of the... 
cancer treatment | CHEMISTRY, MEDICINAL | COMBINATION THERAPY | PHASE-II | TUMOR-CELLS | OPEN-LABEL | chemotherapy | CANCER | GROWTH-FACTOR RECEPTOR | CETUXIMAB | MELANOMA | IMMUNE CHECKPOINTS | ONCOLOGY | immunotherapy | Head and neck cancer | monoclonal antibody | CISPLATIN PLUS FLUOROURACIL | squamous cell carcinoma
Journal Article
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 11/2018, Volume 6, Issue 1, pp. 134 - 8
BackgroundAGI-101H is an allogeneic gene modified whole cell therapeutic melanoma vaccine, evaluated in over 400 melanoma patients in the adjuvant and... 
COLONY-STIMULATING FACTOR | Melanoma | TUMOR | Long-term survivals | IMMUNOLOGY | COMBINATION | Phase II clinical trials | Genetic melanoma vaccine | GENE | ONCOLOGY | DESIGNER CYTOKINE | Immunotherapy | PROSTATE-CANCER | CHECKPOINT | Re-induction | BLOCKADE | IPILIMUMAB | Care and treatment | Diagnosis | Dendritic cells | Surgery | Stem cells | Clinical trials | Metastasis | Prostate cancer | Tumors
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.